Vanguard Personalized Indexing Management LLC Invests $205,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Vanguard Personalized Indexing Management LLC bought a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 6,325 shares of the biotechnology company’s stock, valued at approximately $205,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in shares of Corcept Therapeutics by 90.6% during the 1st quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 579 shares during the last quarter. Park Place Capital Corp bought a new position in shares of Corcept Therapeutics in the 2nd quarter worth approximately $32,000. Atwood & Palmer Inc. bought a new position in shares of Corcept Therapeutics in the 2nd quarter worth approximately $35,000. FinTrust Capital Advisors LLC lifted its stake in shares of Corcept Therapeutics by 318.7% in the 1st quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,348 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of Corcept Therapeutics by 125.4% in the 2nd quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 1,962 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Gary Charles Robb sold 3,101 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $35.71, for a total transaction of $110,736.71. Following the completion of the sale, the insider now directly owns 23,190 shares of the company’s stock, valued at approximately $828,114.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Corcept Therapeutics news, insider Gary Charles Robb sold 3,101 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $35.71, for a total transaction of $110,736.71. Following the completion of the sale, the insider now directly owns 23,190 shares of the company’s stock, valued at approximately $828,114.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider William Guyer sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the sale, the insider now directly owns 6,039 shares of the company’s stock, valued at $213,176.70. The disclosure for this sale can be found here. Insiders sold a total of 23,251 shares of company stock valued at $856,212 in the last three months. 20.50% of the stock is currently owned by corporate insiders.

Corcept Therapeutics Trading Up 5.3 %

NASDAQ CORT opened at $46.28 on Tuesday. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $47.33. The stock has a market cap of $4.82 billion, a price-to-earnings ratio of 43.66 and a beta of 0.45. The company’s 50 day moving average is $36.63 and its two-hundred day moving average is $30.93.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Monday, July 29th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.09. Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%. The company had revenue of $163.80 million for the quarter, compared to analysts’ expectations of $155.14 million. During the same quarter last year, the business earned $0.25 EPS. The firm’s revenue was up 39.1% compared to the same quarter last year. Sell-side analysts forecast that Corcept Therapeutics Incorporated will post 1.12 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CORT shares. HC Wainwright increased their price objective on shares of Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Canaccord Genuity Group reiterated a “buy” rating and issued a $38.00 price objective on shares of Corcept Therapeutics in a research note on Tuesday, July 30th. Truist Financial increased their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Piper Sandler increased their price objective on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $56.50.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.